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Low molecular weight oligomers of amyloid beta (Ab) are important drivers of Alzheimer’s disease. A
decrease in Ab monomer levels in human cerebrospinal fluid (CSF) is observed in Alzheimers’ patients
and is a robust biomarker of the disease. It has been suggested that the decrease in monomer levels in
CSF is due to the formation of Ab oligomers. A robust technique capable of identifying Ab oligomers in
CSF is therefore desirable. We have used fluorescence correlation spectroscopy and a five Gaussian dis-
tribution model (5GDM) to monitor the aggregation of Ab1–42 in sodium phosphate buffer and in artificial
cerebrospinal fluid (ACSF). In buffer, several different sized components (monomer, oligomers, protofi-
brils and fibrils) can be identified simultaneously using 5GDM. In ACSF, the faster kinetics of fibrillogen-
esis leads to the formation of fibrils on very short timescales. This analysis method can also be used to
monitor the aggregation of other proteins, nanoparticles or colloids, even in complex biological fluids.
 2014 Elsevier Inc. All rights reserved.1. Introduction
The accumulation of fibrils formed from the amyloid beta-pro-
tein (Ab) is a defining pathological hallmark of Alzheimer’s disease
(AD) [1]. However, recent evidence suggests that low molecular
weight (MW) diffusible aggregates of Ab (commonly referred to
as Ab oligomers) are more important drivers of AD than the Ab
fibrils found in amyloid deposits [2–4]. Several studies have shown
that small protein aggregates are cytotoxic and contribute to syn-
aptic dysfunction [5–10]. In nature, there are at least 20 different
Ab alloforms all of which have the same common core of about
30 residues, but differ in the length of their N- and C-termini
[11]. Within this family of peptides, primary sequences terminat-
ing at Ala42 are particularly associated with AD [12].
A lowering of Ab1–42 monomer levels in human cerebrospinal
fluid (CSF) has been widely validated as a robust biomarker for
the diagnosis of AD [13], including in pre-symptomatic individualsthat subsequently developed AD [14,15]. Mechanistically, the pro-
gressive accumulation of both soluble and insoluble Ab aggregates
has been postulated to explain the decline in Ab1–42 monomer
observed in CSF. Consequently, it is believed that measurement
of Ab oligomer levels in CSF could offer an even more sensitive
indicator than current biomarkers [13]. Despite intense efforts
there are currently no validated, reliable and sensitive means to
detect Ab oligomers in CSF. The oligomerization and subsequent
formation of protein fibrils of Ab is a complex interplay of many
peptides and mechanisms and is not yet fully understood
[16–20]. However, the majority of studies find that the mechanism
for fibrillogenesis is consistent with a nucleation-dependent poly-
merization model [5,18,21] as illustrated in Fig. 1(A). More recent
work has suggested that a second nucleation step occurs [22].
The major difficulty in monitoring the progression of Ab fibrillo-
genesis is the range of particles sizes present. Even at the early
stages of fibrillogenesis Ab will exist as monomer, heterogenous
oligomers, protofibrils and fibrils. Few techniques can measure
and track the components of such a heterogenous mixture of dif-
ferent sized species simultaneously. Several methods have been
used to map the progression of peptide aggregation, from mono-
mer to fibril, including, high performance liquid chromatography,
gel electrophoresis, atomic force microscopy, transmission elec-
tron microscopy (TEM), Thioflavin T assays, dynamic light scatter-
ing and others [16]. Monomeric Ab has a hydrodynamic radius (Rh)
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Fig. 1. (A) The standard nucleation-dependent polymerization (single nucleation)
model for amyloid aggregation: formation of fibrils proceeds through a multistage
process. Monomers (1) form low molecular weight aggregates (2), then higher
molecular weight aggregates (3) in the nucleation stage, which has a characteristic
lag time before the formation of protofibrils (4) and fibrils (5). A secondary
nucleation step leading to the formation of oligomers via a fibril-catalyzed process
has also been suggested [22] (not shown). (B) The confocal volume for FCS
measurements: fluorescently labeled monomers and peptides diffuse into and out
of the confocal volume leading to fluctuations in the fluorescence signal.
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from several nanometers to several microns [16–19].
It is challenging to quantitatively measure the sizes of different
oligomers, which co-exist with Ab monomer, protofibrils and
fibrils during a typical measurement. Fluorescence correlation
spectroscopy (FCS) can be used to differentiate multiple compo-
nents in a polydisperse solution and has already been used to study
the aggregation of other amyloidogenic proteins. Notably, the
aggregation of polyglutamine in cells [24], a-synuclein aggregation
[25] and its binding to vesicles [26] have been studied. In relation
to Ab, FCS has been used to establish an in vitro saturation concen-
tration of Ab1–40 [27], to test the interaction with aggregation
inhibitors [28] and membranes [29,30], to study the depletion of
oligomers under physiological conditions [23] and to determine
the size distribution of Ab1–40 aggregates in solution [27,31,32].
Garai et al. [27] used a maximum entropy fitting method (MEM-
FCS), which allowed multiple aggregating species within the sys-
tem to be analyzed. While this is an improvement over standard
fitting methods, it did not distinguish clearly between the oligo-
meric species in solution. Therefore, a need for a fitting procedure
which can distinguish more clearly the different sized forms of Ab
during fibrillogenesis exists.
Here, we have approached this problem by defining several
sizes ranges (up to five) as Gaussian profiles (5GDM) and using
these to fit the FCS autocorrelation function. This allows each
pre-defined component to be fit to the data simultaneously, allow-
ing more of the different sized components in the aggregating sys-
tem to be determined at any particular time point during the
experiment. The size distributions obtained using 5GDM analysis
are compared to those obtained using MEMFCS. To our knowledge
no previous work has used such a high number of Gaussian-shaped
peaks and the same free variables for analysis of FCS data for poly-
disperse systems. This approach is not specific to Ab, and we
expect that it will be readily applied to study of other aggregating
or amyloidogenic proteins.delay time τ [µs]
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Fig. 2. Normalized average correlation curves over 48 h for a 20 lM Ab1–42 sample
(0.01% labeled). During the experiment the curves shift to the right and a buckling
develops, indicating an increase in the number of different species and of particle
sizes.2. Material and methods
2.1. Sample preparation
Synthetic Ab1–42 was purchased fromW. M. Keck Biotechnology
Facility at Yale University and Hilyte Fluor488™ labeled Ab1–42 was
purchased from Anaspec Inc., Fremont (CA). The latter was dis-
solved in 1% NH4OH and diluted to a final concentration of 1 mg/
ml in 10 mM sodium phosphate buffer [33]. Ab1–42 was dissolved
in 0.1% NH4OH and then diluted with 100 mM Tris buffer at1 mM, aliquoted and stored at 20 C. Once thawed, peptide solu-
tions were centrifuged at 100,000g and 4 C for 1 h in a Beckman
Optima Max XP ultracentrifuge (Indianapolis, IN) to remove pre-
existing fibrils. The upper 75% of the supernatant was collected
and the concentration of Ab1–42 determined by absorbance at
275 nm. Thereafter the supernatant was further diluted to the
desired concentrations using 10 mM sodium phosphate buffer or
artificial CSF (119 mM NaCl, 26.2 mM NaHCO3, 2.5 mM KCl,
1 mM NaH2PO4, 1.3 mM MgSO4-7H2O, 11 mM D-(+)-Glucose and
2.5 mM CaCl2.2H2O, pH adjusted to 7.3–7.4).
2.2. FCS experiments
FCS measurements were performed on a LSM10 microscope
equipped with a ConfoCor2 unit (Carl Zeiss Jena, Germany), a
488 nm Argon laser and an apochromatic 40 water-immersion
objective with a NA of 1.2. Fluorescence emission was separated
from laser light using a bandpass filter (505–550 nm). Calibration
was performed with Alexa 488 to determine the dimensions of the
observation volume. Samples were filled in NUNC 8-Well-Plates
(Thermo Scientific), which were coated with 15 lg/ml poly-L-lysine
(BiochromAG). All measurementswere performed at room temper-
ature. Autocorrelation functions obtained from FCS measurements
were analyzed as described in Supplementary information.
3. Results and discussion
3.1. Aggregation of Ab1–42 in sodium phosphate buffer
The aggregation of Ab1–42 was measured at 10 and 20 lM in the
presence of 0.01% labeled Ab1–42 in 10 mM sodium phosphate buf-
fer, pH 7.4 by FCS. Variability in the time before onset of oligomer
formation can depend on preparation conditions [16], and/or addi-
tional stresses applied to the sample to speed up the process
[25,34–36]. Measurements were taken systematically over 48 h
using consistent preparation methods to minimize these effects.
Fig. 2 shows the evolution of an autocorrelation function over
the time course of a typical experiment. This sample, at 20 lM,
indicates that higher MW species appear over several hours,
indicated by a shift in the delay time to higher values.
3.2. Comparison of MEMFCS and 5GDM fitting
Beyond the first few measurements, a one-component fit (SI Eq.
(2)) leads to unsatisfactory and physically unrealistic results (not
shown). Thus, a more sophisticated fitting method is required.
J.J. Mittag et al. / Biochemical and Biophysical Research Communications 448 (2014) 195–199 197We first applied the MEMFCS fitting method [27,37] to autocorre-
lation functions at different time points throughout the experi-
ment (Fig. 3A). A fit of the first measurement, reveals a single
peak with a Rh maximum at 1.44 nm and a shoulder towards larger
hydrodynamic radii. After 48 h, three peaks corresponding to
spherical hydrodynamic radii of 2.09 nm, 101.17 nm and 4.5 lm
were observed (Fig. 3E).
Due to the assumption of maximum uncertainty and to avoid
over interpretation of the data, MEMFCS fitting finds the widest
size distribution that is consistent with the data [37]. Thus, the
broad peaks obtained with MEMFCS are likely to include size dis-
tribution data for several different species in solution. Distribution
curves resulting fromMEMFCS analysis show Gaussian-type distri-
bution features. Therefore, we used a Gaussian-shaped size distri-
bution with a fixed number of peaks to fit our experimental data.
This was inspired by initial work by Pal et al. [38], who used this
approach as an alternative to MEMFCS for microemulsion droplets.
The idea is that a component is not monodisperse with a single
value for the diffusion time, sD, but rather a Gaussian distribution
on a logarithmic time-scale with a peak diffusion time sP. The fit to
the autocorrelation function is described by:
GðsÞ ¼
Xn
i¼1
aiðsDiÞ 11þ ssDi
 !
1
1þ sx2sDi
 !1
2
ð1Þ
with the amplitude distribution
aiðsDiÞ ¼
Xk
n¼1
An exp  lnðsDiÞ  lnðsPnÞbn
  
ð2Þ
where An is the relative amplitude of the components, sPn is the
peak diffusion time of the nth component and bn is related to the
width of the distribution. The sD’s have the same logarithmic
quasi-continuous distribution as for MEMFCS. We have extended
the work of Pal et al. by varying An, sPn and bn rather than using onlyre
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Fig. 3. Size distribution obtained with (A) MEMFCS and (B) 5GDM. Both fitting methods
especially in the range of low MW oligomers. Measurements at 0 h, 5 h, 16 h, 20 h, 40 h an
for (C) 0 h, (D) 20 h and (E) 48 h. Both fitting methods show the same trends.a single peak. The fraction of each of the components was then
determined by calculating the areas under the Gaussian peaks and
normalizing them by the sum of the peak areas:
Fractionn ¼ areanPk
n¼1arean
ð3Þ
Hence, each distribution in the Gaussian distribution model
(GDM) will represent a narrow range of particle sizes. The validity
of the GDM was verified by extensive testing of the well-known
dye Alexa 488 (using one distribution successfully, whereas a
higher number of distributions were rejected by the model cor-
rectly). We choose to use five peaks for the fitting of Ab since this
was a good balance between distinguishing the different species in
solution (monomer, small oligomer, larger oligomer, protofibril
and fibril) and not having so many free variables that the outcome
of the fits was physically unrealistic. Analysis of many autocorrela-
tion curves using this method, gave consistent results. Less than
five peaks led to an inappropriate description of the system (i.e.
component sizes smaller than monomeric Ab concomitant with
very large particles at early time points).
In Fig. 3B the results of the analysis with the 5GDM are pre-
sented. There are a larger number of more sharply defined peaks
representing different levels of Ab1–42 aggregation than for MEM-
FCS. 5GDM fits reveal that two peaks at 1.17 nm and 1.62 nm are
present at early time points in the experiment. If a weighted sum
of these first two peaks is calculated using the relative amplitudes,
a Rh of 1.44 nm is determined. This corresponds exactly to the dif-
fusion time for the first peak obtained using MEMFCS fitting. In
Fig. 3C–E, a direct comparison of the results of both fitting methods
is shown for measurements taken at 0 h, 20 h and 48 h. For all
three time points the results of 5GDM and MEMFCS are in good
agreement and show the same trends for the aggregating system.
However, at the later time points (48 h) significant differences
for the calculated size of fibrils are observed (Rh = 4.5 lm for MEM-
FCS and Rh = 0.85 lm for 5GDM). These particle sizes are beyond.02
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show similar trends, but the GDM fitting provides sharper and more defined peaks,
d 48 h. (C–E) direct comparison of the results of MEMFCS (dashed) and 5GDM (line)
198 J.J. Mittag et al. / Biochemical and Biophysical Research Communications 448 (2014) 195–199the reasonable measureable range for FCS and the values are arti-
facts of the fitting procedure in both methods. A comparison of the
results obtained for each fitting procedure is shown in Fig. 3C–E.
Clearly the general features of the aggregating system are consis-
tent using both methods, but the 5GDM provides a more detailed
and potentially a more realistic description of the aggregating sys-
tem with better resolution of low MW species.3.3. Evaluation of the four fractions of Ab1–42 aggregates
5GDM reveals a larger number of species within the system
than MEMFCS, but each of these species represents a range of par-
ticle sizes. Since the first two peaks fuse and separate several times
during the experiment, it was impossible to analyze these fractions
separately (Fig. 3D and E). Hence, the percentages of the first two
peaks were pooled and treated as one. This leads to a four level
fraction model for Ab1–42 aggregation (although a five peak fitting
formula is used). The fusion of these first two peaks is probably due
to a dynamic equilibrium that is assumed between monomers and
very small oligomers [39,40]. We have therefore defined each of
the size ranges obtained from the fitting as: (1) small components
including monomers and low MW oligomers; (2) higher MW oligo-
mers; (3) protofibrils and (4) fibrils. The fractions of the various Ab
particles in solution were determined from the 5GDM fitting and
calculated using Eq. (3). The fractions were monitored over time
and the averaged values are shown in Fig. 4.
The rate of aggregation is slower in the lower concentration
samples and is consistent with previous experiments [32]. After
48 h, the proportion of fraction 1 (monomer and small oligomers)
is higher in the lower concentration samples (72.4 for 10 lM com-
pared to 64.9% for 20 lM), with a corresponding lower proportion
of fibrils (3.6% for 10 lM and 7.5% for 20 lM). The proportion of
fraction 1 decreases as fibrillogenesis proceeds (Fig. 4), while the
Rh stays relatively constant (Fig. S1). Combined, these observations
indicate a real decrease of the amount of monomer/small oligo-
mers in solution. In Fig. S1 the evolution of the two peaks, which
we have called fraction 1 (monomer and small oligomer) is shown.
We observe that only a few data points lie in the monomer range
between 0.8 and 1 nm [23], andmost of the data points lie between
1 and 2 nm. This size range represents mixtures of monomers and
small oligomers. Therefore with 5GDM it is not possible to differ-
entiate between monomers and small oligomers and hence we
have pooled this data in fraction 1. However, we can clearly sepa-
rate a mixture of monomers and low MW oligomers from larger
aggregates. At the beginning of an experiment the dominating spe-100
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Fig. 4. Development of the fractions of the four aggregate levels of Ab1–42 in sodium
phosphate buffer, dashed lines represent 10 lM Ab samples, solid lines represent
20 lMmeasurements. The amount of small components/monomers decreases over
time, while the amount of protofibrils and fibrils increases after a certain lag time.
The fraction of high MW oligomers stays constant. The experiments were preformed
in triplicate to ensure reproducibility.cies are small components (Fig. 4). This starting material consists of
a mixture of monomer and small oligomers. Monomeric samples
did not aggregate on a reasonable experimental time scale [23].
Examining fraction 2 (higher Mw oligomers), we see that these
remain constant throughout the experiment (Fig. 4) (14% for
10 lM and 19% for 20 lM). For this fraction, the Rh grows slowly
in size, and is in the range of 10 nm (Fig. S2). Hence, before the first
measurement, equilibrium between small components (fraction 1)
and high MW oligomers (fraction 2) is established.
Protofibrils or fibrils are not present in FCS data at the beginning
of the experiment (Fig. 4), but appear after a lag time, consistent
with a nucleation-dependent polymerization model [41]. Both spe-
cies show a sigmoidal behavior and a mean lag time of 16 h. The
fraction of protofibrils reaches a saturation level of 10% at 20 lM
and 8% at 10 lM, respectively, while the proportion of fibrillar
material continues to increase to the end of the experiment. Trans-
mission electron microscopy (TEM) confirmed fibril formation
(Fig. S3). The presence of fibrils is consistent with 5GDM analysis
and the size values obtained for fibrils are in agreement with pub-
lished studies [5,42,43].
3.4. Preliminary experiments in artificial CSF
Using artificial cerebrospinal fluid (ACSF), we assessed if the
5GDM fitting procedure is suitable for analysis in complex buffers
and potentially in biological fluids. Large sedimenting particles are
observed immediately after mixing stock Abwith ACSF. During FCS
measurements, this manifests as decreasing particle numbers due
to loss of material to the large aggregates. The remaining mono-
meric material, now at much lower concentration, does not pro-
ceed to form higher MW oligomers, since it is below the
concentration required for the onset of fibrillogenesis. The higher
ionic strength of ACSF leads to much faster kinetics for fibrillogen-
esis of Ab1–42 in lM concentrations [36]. An incremental decrease
in Ab, to nM concentrations, failed to find a regime in which a
broader distribution of particles sizes was observed. Furthermore,
adding labeled Ab to pre-aggregated samples in ACSF produced
similar results. In these experiments, only single events in the
count rate plots were observed for 1 lM, 500 nM and 50 nM Ab1–
42, and these bursts corresponded to fibrils rather than to oligo-
mers. A systematic evaluation with 5GDM was not performed,
since these single events do not meet the requirements of the sta-
tistical basis needed for quantitative FCS analysis. These observa-
tions are consistent with Nag et al. [23]. They suggested that
Ab1–42 aggregation is dependent on physiological factors at low
concentrations of Ab1–42 and that aggregates dissociate below a
certain concentration because they are thermodynamically unsta-
ble. However, beyond the limitation of this experimental system,
there are no technical barriers to using 5GDM analysis in ACSF,
CSF or other complex biological fluids.
A new fitting procedure for FCS (5GDM), allowing several differ-
ent sized components in solution to be analyzed simultaneously
has been developed to study the fibrillogenesis of Ab1–42. Four
Ab1–42 aggregate types in solution were identified; small compo-
nents (including monomer and low molecular weight oligomers),
high MW oligomers, protofibrils and fibrils. Each component was
observed in solution over 48 h for a range of protein concentra-
tions. A comparison with MEMFCS analysis confirmed that the
results obtained with 5GDM are consistent with the established
method, but that better resolution of particle size distributions in
the nm range were obtained using 5GDM. Given that oligomers
of Ab in CSF have been found at picogram levels [44], concentration
of the sample to pM levels could facilitate measurements in CSF
using FCS with 5GDM. This analysis method could also be usefully
employed to monitor the aggregation of other proteins, nanoparti-
cles and colloids.
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